Business Wire06.01.18
Micro Medical Solutions (MMS), an innovator in the field of microvascular interventions that improve clinical outcomes and quality of life, has completed building a Scientific Advisory Board that includes six international leaders in treatment of peripheral artery disease (PAD) and critical limb ischemia (CLI). Formation of this dedicated group of physicians positions MMS to plan and carry out clinical trials and explore new treatment advances.
“We are excited to bring this group of highly esteemed physicians on to our Advisory Board,” said MMS Chief Medical Officer Dr. Jihad Mustapha. “PAD and CLI affect millions. Nearly 25 percent of people with CLI will undergo limb amputation,1 and that number continues to rise.2 Just like each physician on our board who battles PAD and CLI, MMS has a mission to reduce preventable amputations. The Scientific Advisory Board will guide current clinical studies for MicroStent and other technologies in development, helping MMS to develop new treatments that save limbs and improve lives.”
“The formation of the MMS Scientific Advisory Board represents an integral step in our clinical progress and strategic positioning for the future,” noted MMS CEO Gregory Sullivan. “We can now draw on the clinical experience and vision of six world leaders in PAD and CLI treatment at a critical time, as MicroStent enters a clinical study in the U.S. and completes first-in-man cases abroad. With the board’s guidance and new additions to our leadership team in Clinical Affairs, the company continues to build momentum toward our goal of reducing amputations worldwide.”
The following physicians now sit on the MMS Scientific Advisory Board:
Members of the MMS Scientific Advisory board are already providing guidance for international studies and a pivotal trial of MicroStent in the United States. An inaugural meeting is planned for 2018.
Micro Medical Solutions provides solutions to some of the most pressing unmet needs in microvascular intervention by helping to significantly reduce the rate of amputations, improve clinical outcomes and patient quality of life, and minimize the financial and human costs associated with the treatment of peripheral artery disease and critical limb ischemia.
References
1. Henry AJ, Hevelone ND, Belkin M, Nguyen LL. Socioeconomic and hospital-related predictors of amputation for critical limb ischemia. J Vasc Surg. 2011 Feb;53(2):330-9.e1.
2. Baser O, Verpillat P, Gabriel S, et al. Prevalence, incidence, and outcomes of critical limb ischemia in the US Medicare population. Vasc Dis Mgmt. 2013:10;E26-36.
“We are excited to bring this group of highly esteemed physicians on to our Advisory Board,” said MMS Chief Medical Officer Dr. Jihad Mustapha. “PAD and CLI affect millions. Nearly 25 percent of people with CLI will undergo limb amputation,1 and that number continues to rise.2 Just like each physician on our board who battles PAD and CLI, MMS has a mission to reduce preventable amputations. The Scientific Advisory Board will guide current clinical studies for MicroStent and other technologies in development, helping MMS to develop new treatments that save limbs and improve lives.”
“The formation of the MMS Scientific Advisory Board represents an integral step in our clinical progress and strategic positioning for the future,” noted MMS CEO Gregory Sullivan. “We can now draw on the clinical experience and vision of six world leaders in PAD and CLI treatment at a critical time, as MicroStent enters a clinical study in the U.S. and completes first-in-man cases abroad. With the board’s guidance and new additions to our leadership team in Clinical Affairs, the company continues to build momentum toward our goal of reducing amputations worldwide.”
The following physicians now sit on the MMS Scientific Advisory Board:
- Robert Beasley, MS, M.D.—Director of the Vascular/Interventional Radiology and Vein Treatment Center, Mt. Sinai Medical Center, Miami Beach, Fla.
- Marianne Brodmann, M.D.—Professor of Internal Medicine, Division of Angiology, Medical University Graz, Graz, Austria
- Mahmood K. Razavi, M.D.—Medical Director, Comprehensive Aortic Center; Director, Department of Clinical Trials, St. Joseph Heart & Vascular Center, Orange, Calif.
- Andrej Schmidt, M.D.—University Hospital of Leipzig, Leipzig, Germany
- Craig Walker, M.D.—Founder, president, and medical director, Cardiovascular Institute of the South, Houma, La.; Chairman, New Cardiovascular Horizons
- Thomas Zellar, M.D., Ph.D.—Department of Angiology, Clinic Cardiology-Angiology II, University Heart Center, Freiburg-Bad Krozingen, Germany
Members of the MMS Scientific Advisory board are already providing guidance for international studies and a pivotal trial of MicroStent in the United States. An inaugural meeting is planned for 2018.
Micro Medical Solutions provides solutions to some of the most pressing unmet needs in microvascular intervention by helping to significantly reduce the rate of amputations, improve clinical outcomes and patient quality of life, and minimize the financial and human costs associated with the treatment of peripheral artery disease and critical limb ischemia.
References
1. Henry AJ, Hevelone ND, Belkin M, Nguyen LL. Socioeconomic and hospital-related predictors of amputation for critical limb ischemia. J Vasc Surg. 2011 Feb;53(2):330-9.e1.
2. Baser O, Verpillat P, Gabriel S, et al. Prevalence, incidence, and outcomes of critical limb ischemia in the US Medicare population. Vasc Dis Mgmt. 2013:10;E26-36.
